RenovoRx, Inc. Common Stock
RNXTStockNASDAQ
$0.84 ▼ 2.41%
Jun 12, 2026
R
RenovoRx, Inc. Common Stock
$0.84 ▼ 2.41%
Jun 12, 2026
RNXTStockNASDAQ

About the company

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Arberion
Loading market data